The Global Forum on Translational and Applied Innovations in Life and Health will take place on November 29, 2026, at Sun Yat-sen University in Guangzhou, China. Under the theme “Life & Health: Empower. Translate. Share,”
the event will examine clinical applications, research translation and cross-border collaboration in innovative pharmaceuticals and medical devices, exploring how scientific advances can become products and solutions used in medical practice.
The forum is jointly organized by the Sun Yat-sen University Biomedical Alumni Industry Alliance, Guangzhou Shenlan Health Science Co., Ltd., the Guangdong Institute of Advanced Biomaterials and Medical Devices, and the Guangdong Academy of Modern Southern Medicine. The School of Biomedical Engineering at Sun Yat-sen University and CPEO provide guidance. The Icons is the forum’s Official International Media Partner and will follow the connections between life and health innovation in China and international clinical, research and industry resources.
From Research to Medical Practice, Translation Is A Shared Challenge
For healthcare institutions, research teams and industry investors, connecting a technology’s scientific merit with its practical value requires work at several stages. Whether laboratory results can be validated in clinical settings, whether a product can be manufactured consistently and whether it fits into treatment workflows are questions that must be addressed before an innovation reaches routine use.
The forum brings clinical practice, regulation and industrial translation into a shared discussion. Sessions will address medical device evaluation, clinical experience, market access for innovative pharmaceuticals and devices, and international industry collaboration. A panel on “Clinical Breakthroughs and Future Pathways in Translating Innovative Pharmaceuticals and Medical Devices”
will focus on the links between hospitals, research institutions and companies.
These questions extend beyond China. Healthcare systems differ in their needs, evaluation methods and conditions of use. Taking a research outcome into a new setting requires a clear account of the problem it addresses, the evidence behind it and the partners responsible for further development. Cross-border collaboration consequently involves an exchange of clinical experience, research methods and specialist capabilities as well as technologies and products.

Industry Networks And Research Institutes Connect Development with Application
The backgrounds of the four joint organizers highlight an important feature of research translation: finding suitable partners must be accompanied by access to institutions capable of sustaining research, evaluation and product development.

The Sun Yat-sen University Biomedical Alumni Industry Alliance draws on its alumni network to connect research, clinical practice, businesses and capital. Its exchange activities have covered in vitro diagnostics, recombinant proteins, AI-enabled medical devices and brain–computer interfaces. For researchers and companies seeking collaborators, a specialist alumni network can connect participants across disciplines and bring technical needs into direct discussion with industry resources.

The Guangdong Institute of Advanced Biomaterials and Medical Devices focuses on technology development, regulatory science and engineering translation. Established by South China University of Technology, it works in biomaterials, advanced implantable and interventional devices, AI-enabled medical equipment and regenerative medicine. Its activities span frontier research and proof of concept through clinical evaluation and industrial development.

Guangzhou Shenlan Health Science Co., Ltd. works in healthspan management, tissue repair and the translation of cell-related technologies. Its core team includes specialists from academia, industry and investment, bringing perspectives on developments in mainland China’s life and health sector to business questions about organizing R&D, identifying applications and pursuing commercialization.

The Guangdong Academy of Modern Southern Medicine works on research, technology transfer and industry services related to southern Chinese medicinal resources, extending the discussion to their contemporary study and application.
International Collaboration Requires Specific Markets And Clear Responsibilities
Market access for innovative pharmaceuticals and medical devices in ASEAN countries is a key topic at the forum. It connects the international application of Chinese innovations with the healthcare needs and market conditions of individual countries.
For Chinese research institutions and companies, collaboration requires an understanding of what a target market needs and what additional research and evaluation an existing technology may require. For international healthcare and industry organizations, Chinese research teams, hospitals and development platforms may also be partners in joint research and product development. A starting point is a clear account of each party’s needs, capabilities and responsibilities.
Discussions of clinical applications, regulatory experience and market access will provide room to examine those questions directly. The value of cross-border collaboration also depends on specific tasks: which technologies warrant further investigation, which clinical problems can be explored together and which development stages can be undertaken jointly.
Co-organizers include HEALTH BioMed Co., Ltd.; Wuhan ABclonal Biotechnology Co., Ltd.; Guangzhou Changdu Medical Laboratory Co., Ltd.; the Guangdong Institute for Emerging Cerebrovascular Disease Therapeutic Devices; the Sun Yat-sen University Medical–Engineering Innovation Association; the Guangdong–Hong Kong–Macao Greater Bay Area Life Sciences Industry Promotion Association; the Guangdong Huilai Chamber of Commerce; and the Guangzhou Productivity Promotion Center. Their participation extends the exchange beyond technical cooperation to resource matching and industry support services.
The Icons Will Examine How Innovation Becomes Lasting Collaboration
As Official International Media Partner, The Icons will cover three connected dimensions of the forum: clinical value, translation mechanisms and international collaboration. Its reporting will examine how medical needs shape research priorities, how evaluation and regulation connect with product development, and how institutions in different countries organize cooperation around specific projects.
Understanding China’s role in international life and health innovation requires attention to particular technologies, clinical evidence and execution capabilities. For research teams, translation takes scientific work into a new stage of validation. For hospitals and companies, it requires a shared judgment about whether a technology merits adoption and how responsibility for development and use should be allocated.
Editor’s Picks
From Code to Cure: How AI, Cellular Reprogramming, Capital and Global Markets Are Converging